Raffaela Miriam Planka

Dr. Raffaela Miriam Planka

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 May 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
RPRaffaela Miriam Planka
Raffaela Miriam Planka
AHAlmuthe Christine Hauer
Almuthe Christine Hauer
SBSebastian Bauchinger
Sebastian Bauchinger
BKBenno Kohlmaier
Benno Kohlmaier
Background: Due to dysbiosis, intestinal barrier dysfunction, and immunosuppressive therapy, pediatric inflammatory bowel disease (PIBD) patients are more susceptible to infections. However, data on bacterial gastrointestinal (GI) infections in this population are scarce, and no guidelines explicitly address immunosuppressive therapy management during such infections. This single-center study aims to address these knowledge gaps. Methods: A retrospective study of bacterial GI infections was conducted in PIBD patients aged 0–18 years, treated between 2011 and 2021 at the Department of Pediatrics and Adolescent Medicine, Medical University of Graz. Data to assess the study endpoints were extracted from the hospital information system. Results: A total of 139 PIBD patients were screened for bacterial GI infections. The mean follow-up time was 49 months (standard deviation ±33) and the total follow-up time amounted to approximately 473 person-years. Fourteen patients developed infections, with three experiencing them twice, resulting in 17 cases of infection. Most infections were caused by opportunistic bacteria, and 10 infections were treated with antibiotics (11 antibiotic prescriptions in total). At infection onset, 12 patients were on (combined) immunosuppressive therapy, including corticosteroids (3 patients), immunomodulators (9 patients), and/or biologics (3 patients). Six infections required escalation of immunosuppressive therapy due to increased PIBD activity. Hospitalization was required in five cases, and one Clostridioides difficile infection progressed to sepsis, necessitating intensive care unit admission. This corresponds to an incidence of three infections (95% confidence interval 1.75–4.80) and 0.2 severe infections per 100 person-years (95% confidence interval 0.01–1.11). Conclusions: The incidence of bacterial GI infections was 3 per 100 person-years (95% confidence interval: 1.75–4.80), with most cases being clinically mild. Clostridioides difficile was the most common pathogen. Immunosuppressive therapy was generally continued or intensified, when necessary, while antibiotic therapy was administered as indicated.

Verified
Journal Article
Open access
PDF file
CSChristoph Strohhofer
Christoph Strohhofer
FAFaisal Aziz
Faisal Aziz
AKAndreas Kainz
Andreas Kainz
ABAndrea Berghold
Andrea Berghold
NVNicolas Verheyen
Nicolas Verheyen
DLDirk Von Lewinski
Dirk Von Lewinski
Background/Objectives: Cardiovascular risk remains substantial after myocardial infarction (MI) despite established clinical risk markers. Erythrocyte and platelet indices are routinely available, but their long-term prognostic relevance remains insufficiently studied. Methods: This retrospective cohort study was based on the Styrian Registry on Genuine Myocardial Infarction (STRONG-MI) and included patients with MI undergoing invasive coronary angiography in Styria, Austria, between January 2007 and March 2016. Multivariable Cox regression models were used to assess the associations of admission and discharge erythrocyte and platelet indices with 3-point major adverse cardiovascular events (MACE) during follow-up extending to 175 months. Results: Among 10,920 patients, admission hemoglobin showed a U-shaped association with MACE. Median hemoglobin decreased from admission to discharge (14.2 g/dL vs. 13.1 g/dL) and the lowest discharge tertile showed the highest association with MACE compared with the middle tertile (AHR 1.27, 95% CI 1.18–1.38). Lower mean corpuscular hemoglobin concentration (MCHC) was independently linked to adverse outcomes at both admission and discharge (AHR 1.17, 95% CI 1.08–1.27, and 1.14, 95% CI 1.05–1.23, respectively). Higher platelet count and mean platelet volume (MPV) were also associated with increased risk, particularly at discharge (AHR 1.15, 95% CI 1.06–1.24, and 1.19, 95% CI 1.10–1.29, respectively). Conclusions: Routine erythrocyte and platelet indices were independently associated with long-term cardiovascular outcomes after invasively treated MI and reflect residual biological risk after discharge.

12 October 2025 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Open access
RPRaffaela Miriam Planka
Raffaela Miriam Planka
LHLukas Herold
Lukas Herold
TGTheresa Glantschnig
Theresa Glantschnig
GSGudrun Sommer
Gudrun Sommer
JPJonathan Pavek
Jonathan Pavek
DLDirk Von Lewinski
Dirk Von Lewinski
Background: The DanGer Shock trial investigated the effects of adding a microaxial flow pump to guideline‐recommended therapy in patients with ST‐elevation myocardial infarction (STEMI)‐related cardiogenic shock (CS), finding a lower all‐cause mortality at 180 days in the intervention group. Methods: DanGer Shock eligibility criteria were applied to the prospective single‐center PREPARE CardShock registry, which consecutively enrolled 721 patients between April 2019 and August 2024 with advanced CS—classified as stages C to E according to the SCAI shock classification—who were on vasoactive medication and underwent cardiac catheterization. Results: Among 721 patients in the registry, 384 (53.3%) had STEMI‐related CS. Of those, 117 (30.5%) met DanGer Shock trial eligibility criteria, accounting for 16.2% of the registry cohort. Median age of the eligible patients was 68 years (interquartile range [IQR]: 58–78), and 62.4% were male, compared to 68 years (IQR: 60–76) and 79.2% in DanGer Shock. PREPRARE‐CS DanGer Shock eligible patients had a higher median systolic blood pressure (SBP) (92 mmHG [78–107] vs. 83 mmHG, [72–91]) and higher median lactate levels (5.2 mmol/L [3.6–7.6] vs. 4.6 mmol/L [3.3–7.0]) at baseline, and were more frequently resuscitated (56.4% vs. 20.3%). Device use was 42.7% in eligible patients. Renal replacement therapy (RRT) was more frequent among trial participants (34.4% vs. 17.1%). The 180‐day mortality rate among eligible patients was 71.8%, compared to 52.1% in trial participants. Conclusions: Among STEMI‐related CS patients in our cohort, only one‐third met the DanGer Shock eligibility criteria. Consequently, trial outcomes may not be broadly applicable.

Verified
Journal Article
Open access
PDF file
MBMartin Benedikt
Martin Benedikt
Markus HerrmannMarkus Herrmann
Markus Herrmann
FAFaisal Aziz
Faisal Aziz
Norbert TripoltNorbert Tripolt
Norbert Tripolt
PPPeter Pferschy
Peter Pferschy
DLDirk Von Lewinski
Dirk Von Lewinski
Background: Sodium glucose-linked transport 2 inhibitors (SGLT2-Is) are well known to exert beneficial effects in chronic heart failure (CHF) independent of left ventricular ejection fraction (LVEF). As inflammation plays a key role in cardiac diseases, data on the association of inflammatory biomarkers and ventricular arrhythmic (VA) burden in SGLT2-I-treated patients is lacking. Methods: This pre-defined subanalysis investigated changes in pre-specified inflammatory biomarkers from baseline to week 52 in response to 5 mg Ertugliflozin compared to placebo and their associations to the incidence of VA burden. Results: A total of 36 patients (18 versus 18) with available biobank samples were included in the analysis. At week 52, leukocyte and neutrophil counts, as well as high-sensitive C-reactive protein (hsCRP) and interleukin-6 (IL-6), were numerically higher in the Ertugliflozin group. In contrast, neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) were lower in the Ertugliflozin group, although these differences did not reach statistical significance. Notably, lymphocyte counts were significantly higher in Ertugliflozin showing a mean difference of 19.0 ± 10.78% (p = 0.028). Further, a significantly higher incidence of VA burden was observed among Ertugliflozin-treated patients with elevated hsCRP levels (incidence rate ratio [IRR] 3.58; 95% Confidence interval [CI], 1.12–11.40, p = 0.031). Conclusions: In patients with CHF, Ertugliflozin treatment was associated with a higher incidence of VA burden in those with elevated hsCRP levels. This may suggest a potential higher risk for VA in SGLT2-I-treated patients in the setting of heightened inflammatory activity. However, this finding is based on a single interaction analysis in a small sample size, and the results should therefore be considered exploratory and hypothesis-generating, and must be interpreted cautiously.